Indian biologics market is estimated to grow at a CAGR of 10.2% during the forecast period. Some pivotal factors encouraging market growth include the rising prevalence of cancer and increasing launches of biologics in the country. A significant rise in cancer incidences has been reported in the country. As per the World Health Organization (WHO), in 2018, nearly 1.1 million new cancer incidences were reported in the country. In 2018, breast cancer accounted for 14.0%, lip, oral cavity (10.4%), cervix uteri (8.4%), lung (5.9%), stomach (5.0%), and other cancers (56.4%) of all new cancer incidences in the country. This, in turn, is driving the adoption of biologics which acts as an immune system substance that supports to augment the body’s ability to fight against cancer. Biologics comprises a comprehensive range of drugs that particularly target cancer cells, encourage the immune response, and support the recovery from cancer treatment. These drugs are normally utilized in combination with other therapies, including chemotherapy.

Free Sample Copy @ https://www.omrglobal.com/request-sample/indian-biologics-market

Indian biologics market is segmented based on product and application. Based on the product, the market is segmented into antibody therapeutics, vaccines, cell therapy, gene therapy, and others. Rising launches of antibody therapeutics are reflecting positively on the market growth. Cadila Pharmaceuticals Ltd., Biocon Ltd., and Cipla Ltd. are some players that are increasingly focusing on launching new monoclonal antibody therapies in the country. Based on application, the market is segmented into cancer, autoimmune diseases, infectious diseases, and others.

A Full Report of Indian Biologics Market is Available at:
https://www.omrglobal.com/industry-reports/indian-biologics-market

The market study of the Indian biologics market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Indian Biologics Market – Segmentation
by Product
Antibody Therapeutics
Vaccines
Cell Therapy
Gene Therapy
Others
by Application
Cancer
Autoimmune Diseases
Infectious Diseases
Others

Company Profiles
AbbVie, Inc.
Aurobindo Pharma, Ltd.
Biocon, Ltd.
Biological E. Ltd.
Boehringer Ingelheim GmbH
Cipla, Ltd.
Hetero Drugs, Ltd.
Lupin, Ltd.
Sun Pharmaceutical Industries, Ltd.
Zydus Healthcare, Ltd.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/indian-biologics-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected] 
Contact no: +91 780-304-0404